Breo Ellipta Shortage Update: What Patients Need to Know in 2026

Breo Ellipta in 2026: What's Going On?

If you've had trouble filling your Breo Ellipta (fluticasone furoate/vilanterol) prescription recently, you're probably wondering: is there a Breo Ellipta shortage? The short answer is no — there is no official FDA-listed shortage of Breo Ellipta as of early 2026. But that doesn't mean finding it is always easy.

In this update, we'll cover the current availability picture, why you might be having trouble, what it costs, and what your options are if your pharmacy doesn't have it.

Is Breo Ellipta Still in Shortage?

Breo Ellipta is not listed on the FDA Drug Shortage Database and has never been the subject of a major supply disruption. GlaxoSmithKline (GSK), the sole manufacturer, continues to produce and distribute the medication.

However, patients across the country have reported intermittent difficulty finding Breo Ellipta at their local pharmacies. These reports are consistent with localized stocking issues rather than a true manufacturing shortage. Factors that contribute to this include:

• Pharmacies reducing stock of expensive brand-name inhalers
• Insurance plans directing patients toward cheaper alternatives through step therapy
• No generic equivalent driving down demand at some locations

For a deeper dive into why this happens, read: Why Is Breo Ellipta So Hard to Find?

Why Is Breo Ellipta Hard to Find?

Several converging factors make Breo Ellipta harder to find than some other inhalers:

Brand-Only Status

Breo Ellipta has no FDA-approved generic as of 2026. This means it's only made by one company (GSK), it's priced as a brand-name drug ($350-$450 per inhaler without insurance), and pharmacies must make deliberate stocking decisions about carrying it.

Formulary Shifts

More insurance plans have been moving patients toward generic ICS/LABA options like Wixela Inhub (generic Advair) and generic Symbicort. When fewer patients at a pharmacy use Breo Ellipta, the pharmacy orders less — creating a self-reinforcing cycle of lower availability.

Single Manufacturer

With no generic competitors, GSK is the only source. Any distribution delays or regional demand spikes can create temporary gaps at individual pharmacies.

How Much Does Breo Ellipta Cost in 2026?

Cost is a major consideration for many patients:

• Cash price (no insurance): $350-$450 per 30-dose inhaler (one month supply)
• With commercial insurance: Typically $30-$75 copay (Tier 3) or $75-$150 (Tier 4), depending on your plan
• With GSK savings card: Eligible commercially insured patients may pay as little as $10-$30 per month
• Medicare Part D: Coverage varies by plan; no manufacturer savings card available for government insurance

For complete cost-saving strategies, see: How to Save Money on Breo Ellipta in 2026

New Options and Developments

While there's no generic Breo Ellipta yet, the respiratory inhaler market continues to evolve:

• Generic Symbicort (budesonide/formoterol) has expanded availability, giving patients a more affordable ICS/LABA option
• Wixela Inhub (generic Advair Diskus) remains widely available and is often the first-line alternative insurers recommend
• Trelegy Ellipta, a triple-therapy inhaler from GSK using the same device, is increasingly popular for COPD patients who need additional bronchodilation
• Several pharmaceutical companies continue to pursue generic versions of Breo Ellipta, though none have received FDA approval yet

How to Find Breo Ellipta in Stock

If your pharmacy is out, don't wait — take these steps:

1. Use Medfinder to check real-time inventory at pharmacies near you
2. Try independent pharmacies — they often have different stocking patterns than chains
3. Ask your pharmacy to special order it — most can get it in 1-2 business days
4. Consider mail-order pharmacy — many insurance plans offer this with lower copays for 90-day supplies

For more detailed tips, check out: How to Find Breo Ellipta in Stock Near You

Final Thoughts

Breo Ellipta is not in a formal shortage in 2026, but localized availability issues can make it feel that way. The combination of brand-only status, high cost, and insurance formulary shifts means patients sometimes have to work harder to get their medication.

Stay proactive: use tools like Medfinder, explore savings programs, and keep an open dialogue with your doctor about alternatives if needed. Your breathing shouldn't suffer because of a pharmacy stocking issue.